171 related articles for article (PubMed ID: 21761341)
1. Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Wang L; Chan MS; Wing L; Yiu CC; Chow LW; Sasano H
Horm Cancer; 2011 Feb; 2(1):73-81. PubMed ID: 21761341
[TBL] [Abstract][Full Text] [Related]
2. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
3. 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production.
Suzuki T; Miki Y; Moriya T; Akahira J; Ishida T; Hirakawa H; Yamaguchi Y; Hayashi S; Sasano H
Int J Cancer; 2007 Jan; 120(2):285-91. PubMed ID: 17066438
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast.
Yoda T; McNamara KM; Miki Y; Takagi M; Rai Y; Ohi Y; Sagara Y; Tamaki K; Hirakawa H; Ishida T; Suzuki T; Ohuchi N; Sasano H
Cancer Sci; 2014 Nov; 105(11):1503-9. PubMed ID: 25230018
[TBL] [Abstract][Full Text] [Related]
6. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
[TBL] [Abstract][Full Text] [Related]
7. Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment.
Takagi K; Miki Y; Nagasaki S; Hirakawa H; Onodera Y; Akahira J; Ishida T; Watanabe M; Kimijima I; Hayashi S; Sasano H; Suzuki T
Endocr Relat Cancer; 2010 Jun; 17(2):415-30. PubMed ID: 20228125
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
Shibuya R; Suzuki T; Miki Y; Yoshida K; Moriya T; Ono K; Akahira J; Ishida T; Hirakawa H; Evans DB; Sasano H
Endocr Relat Cancer; 2008 Mar; 15(1):113-24. PubMed ID: 18310280
[TBL] [Abstract][Full Text] [Related]
9. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation.
McNamara KM; Yoda T; Miki Y; Chanplakorn N; Wongwaisayawan S; Incharoen P; Kongdan Y; Wang L; Takagi K; Mayu T; Nakamura Y; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Ohuchi N; Sasano H
Cancer Sci; 2013 May; 104(5):639-46. PubMed ID: 23373898
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report.
Chow LW; Wong JL; Toi M
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):443-7. PubMed ID: 14623542
[TBL] [Abstract][Full Text] [Related]
11. 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
Suzuki T; Darnel AD; Akahira JI; Ariga N; Ogawa S; Kaneko C; Takeyama J; Moriya T; Sasano H
J Clin Endocrinol Metab; 2001 May; 86(5):2250-7. PubMed ID: 11344235
[TBL] [Abstract][Full Text] [Related]
12. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
13. Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer.
Shibahara Y; Miki Y; Sakurada C; Uchida K; Hata S; McNamara K; Yoda T; Takagi K; Nakamura Y; Suzuki T; Ishida T; Ohuchi N; Sasano H
Hum Pathol; 2013 Oct; 44(10):2338-45. PubMed ID: 23953348
[TBL] [Abstract][Full Text] [Related]
14. New development in intracrinology of breast carcinoma.
Sasano H; Suzuki T; Nakata T; Moriya T
Breast Cancer; 2006; 13(2):129-36. PubMed ID: 16755106
[TBL] [Abstract][Full Text] [Related]
15. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
16. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Glück S
Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
[TBL] [Abstract][Full Text] [Related]
17. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Yiu CC; Chanplakorn N; Chan MS; Loo WT; Chow LW; Toi M; Sasano H
Anticancer Res; 2010 Sep; 30(9):3465-72. PubMed ID: 20944124
[TBL] [Abstract][Full Text] [Related]
19. 5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3.
Negri-Cesi P; Colciago A; Poletti A; Motta M
Prostate; 1999 Dec; 41(4):224-32. PubMed ID: 10544295
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
